ADVERTISEMENT
HER2 and PD-L1 Immunohistochemistry Expression Among Patients With Advanced Bladder Cancer
Featuring David Aggen, MD, PhD
At the 2024 ASCO Genitourinary Cancers Symposium, David Aggen, MD, Memorial Sloan Kettering Cancer Center, New York, New York, shared results from a retrospective analysis describing HER2 and PD-L1 expression and HER2 genomic alterations seen among patients with advanced bladder cancer.
This study found an inverse correlation between HER2 immunohistochemistry expression and PD-L1 combined positive score. These data can provide foundation for further trials in HER2-directed therapies for advanced bladder cancer.
Source:
Aggen DH, Shah NJ, Zheng J, et al. HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer. Presented at the 2024 ASCO Genitourinary Cancers Symposium; January 25-27, 2024; San Francisco, California. Abstract 538
© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Current Issue
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Subscribe
Advertisement
Advertisement
Advertisement
Recent Stories
Advertisement